Search results
AstraZeneca withdraws Covid-19 jab from the market
PA Media: Science via Yahoo News· 6 days ago“There would have been far more deaths, hospitalisations, illness and transmission, if we hadn’t had the AstraZeneca vaccine, alongside the other key...
"FLiRT" COVID variants are now more than a third of U.S. cases. Scientists share what we know about...
CBS News· 4 days agoMore than a third of COVID-19 cases in the U.S. are now estimated to be from a new, fast-growing...
AstraZeneca removes Covid vaccine after very rare side effect linked to deaths
The US Sun· 6 days agoASTRAZENECA has wound down its Covid vaccine and will no longer make or distribute it because the...
CytomX Therapeutics Inc (CTMX) Q1 2024 Earnings Call Transcript
Guru Focus· 6 days agoCytomX Therapeutics Inc (CTMX, Financial) announced positive initial Phase 1a dose escalation data for CX nine oh four, showing promising anti-cancer activity, particularly ...
AstraZeneca withdrawing Covid vaccine, months after admitting rare side effect
The Telegraph via Yahoo News· 7 days agoThe Oxford-AstraZeneca Covid vaccine is being withdrawn worldwide, months after the pharmaceutical...
CytomX Therapeutics Inc (CTMX) Q1 2024 Earnings Call Transcript Highlights: Strategic ...
GuruFocus.com via Yahoo Finance· 5 days agoExplore key financial outcomes and clinical advancements as CytomX Therapeutics Inc (CTMX) navigates through Q1 2024 with robust partnerships and innovative cancer treatments.
The AstraZeneca vaccine – should you be worried?
Daily Telegraph· 3 days agoOverall, the jab has been linked to at least 81 fatalities and hundreds of injuries in the UK, and Dr Michael Head, a global health researcher at the...
CytomX Therapeutics, Inc. (NASDAQ:CTMX) Q1 2024 Earnings Call Transcript
Insider Monkey via Yahoo Finance· 5 days agoCytomX Therapeutics, Inc. (NASDAQ:CTMX) Q1 2024 Earnings Call Transcript May 8, 2024 CytomX...
Q1 2024 CytomX Therapeutics Inc Earnings Call
Thomson Reuters StreetEvents via Yahoo Finance· 5 days agoStrategic...Myers Squibb, Amgen, Astellas, Regeneron and Moderna on multiple Probody therapeutic programs. We continue to be in a strong financial...
Biotech Slumps Despite 'Pristine' Results For Bristol-Rivaling Heart Drug
Investor's Business Daily· 18 hours agoThe company tested its drug, aficamten, in patients with obstructive hypertrophic cardiomyopathy, or...